TABLE 1.
Study cohort characteristics
| Characteristica | No. of patients (%)b
(total = 52) |
|---|---|
| Age, yr [median (IQR)] | 56 (52 − 61) |
| Female | 43 (83) |
| Hispanic | 29 (56) |
| Black | 27 (52) |
| BMI, kg/m2 [median (IQR)] | 28.8 (25 − 32) |
| Normal (18 ≤ BMI < 25) | 16 (31) |
| Overweight (25 ≤ BMI < 30) | 15 (29) |
| Obese (30 ≤ BMI ≤ 35) | 12 (23) |
| Morbidly obese (35 ≤ BMI < 45) | 8 (15) |
| Menopausal status | |
| Premenopausal | 5 (10) |
| Postmenopausal | 38 (73) |
| Hepatitis B | |
| Prior | 8 (15) |
| Current | 7 (13) |
| Smoker | |
| Former | 5 (10) |
| Current | 11 (21) |
| Years since HIV diagnosis | |
| <10 yr | 9 (17) |
| 10–20 yr | 16 (31) |
| >20 yr | 23 (44) |
| History of AIDS | 34 (65) |
| CD4 nadir | |
| <50 cells/μl | 10 (19) |
| <100 cells/μl | 4 (8) |
| <200 cells/μl | 16 (31) |
| ART regimen | |
| NRTI + PI | 15 (29) |
| NRTI + INSTI | 15 (29) |
| NRTI + NNRTI | 13 (25) |
| Periodontal disease severityc | |
| None/mild (≤2 IP sites with CAL > 4 mm) | 4 (8) |
| Moderate (>2 IP sites with CAL > 4 mm) | 16 (31) |
| Severe (>2 IP sites with CAL > 6 mm) | 22 (42) |
| No. of teeth [median (IQR)] | 22 (15 − 26) |
| % teeth with CAL > 4 mm [median (IQR)] | 71 (40 − 99) |
a
Abbreviations: IQR, interquartile range; BMI, body mass index; HIV, human immunodeficiency virus; ART, antiretroviral therapy; NRTIs, nucleoside reverse transcription inhibitors; NNRTI, nonnucleoside reverse transcription inhibitors; PI, protease inhibitors; INSTI, integrase strand transfer inhibitors; IP, interproximal; CAL, clinical attachment loss.
b
Number of patients with percentage shown in parentheses unless IQR specified.
c
Periodontal disease severity categories as defined by the Centers for Disease Control and Prevention (CDC) and the American Academy of Periodontology (AAP).